Omnicell Inc: (NASD: OMCL)
$18.27
0.07 (0.39%)
Volume 153,123
May 23 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Brokerage Recommendations
| Current ABR | 1.67 |
| ABR (Last week) | 1.67 |
| # of Recs in ABR | 6 |
| Average Target Price | $21.50 |
| LT Growth Rate | 16.70% |
| Industry | MEDICAL INFO SYSTEMS |
| Industry Rank by ABR | 199 of 265 |
| Current Quarter EPS Est: | 0.21 |
Premium research
Zacks Rank
|
 2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
199 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 |
| Buy | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Hold | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Sell | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Strong Sell | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| ABR | 1.67 | 1.67 | 1.80 | 1.80 | 1.80 |
Analyst Upgrades/Downgrades
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
